PATIENT INFORMATION LEAFLET (PIL) KATINKO® INHALER

Read all of this leaflet carefully before you start using this medicine.

  • Keep this leaflet. You may need to read it again.

  • If you have any further questions, ask your healthcare provider.

  • If any of the side effects become serious, or if you notice any side effects not listed in this leaflet, please tell your healthcare provider.

PRODUCT DESCRIPTION

Menthol + Camphor 140 mg/40 mg per 2 mL (KATINKO®) Inhaler is a green-colored polypropylene inhaler packed in a blister board.

 

WHAT IS IN THE MEDICINE?

This medicine contains Menthol and Camphor. Another ingredient is Eucalyptus oil used as a solvent.

MENTHOL is a crystalline compound with a cooling and minty odor used to produce surface irritation on the nostril, thereby counteracting underlying discomfort (counterirritant) for the relief of nasal congestion associated with rhinitis and symptomatic relief of shortness of breath (dyspnea).

CAMPHOR is an aromatic crystalline compound used to improve respiratory function and inflammatory conditions caused by nasal congestion.

 

STRENGTH OF THE MEDICINE

See formulation.

 

WHAT IS THIS MEDICINE USED FOR?

Katinko® Inhaler is indicated to help relieve nasal discomfort. Use this medication through inhalation.

HOW MUCH AND HOW OFTEN SHOULD YOU USE THIS MEDICINE?

Use this medication as directed by your doctor or follow all directions on the product package. If you have any questions, talk to your doctor or pharmacist.

 

WHEN SHOULD YOU NOT USE THIS MEDICINE?

If you are allergic to the active ingredients or any other ingredient of Katinko® Inhaler. Do not use it for more than 2 hours and throw it away after 2-3 months of use even if the inhaler smells medicinal, it may cause possible harm. Talk to your pharmacist for more details.

 

Not recommended for children 2 years of age and below, breast feeding mothers and pregnant women, as it has the potential to cause birth defects.

 

CARE THAT SHOULD BE TAKEN WHEN USING THIS MEDICINE

Avoid contact with eyes and mouth. Camphor containing products should not be used on broken or injured skin because the body could absorb toxic substances into the body.

UNDESIRABLE EFFECTS OF THIS MEDICINE

Camphor + Menthol containing products are generally safe for use when inhaled within the recommended dose and duration of treatment. Breathing problems after using this medicine on the chest or throat have been reported. Tell your doctor or pharmacist promptly if any of these effects last or get worse. 

 

WHAT OTHER MEDICINE OR FOOD SHOULD BE AVOIDED WHILE USING THIS MEDICINE?

No listed drug interactions with other drugs. If your doctor has directed you to use this medication, your doctor or pharmacist may already be aware of any possible drug interactions and may be monitoring you for them. Do not start, stop or change the dosage of any medicine before checking with your doctor, healthcare provider or pharmacist first. And please tell your health care provider if you are taking or have recently taken any other medicines, including medicines obtained without a prescription.

 

SIGNS AND SYMPTOMS OF OVERDOSE

Symptoms include redness of the nostrils and feeling light-headed or fainting.

WHAT TO DO WHEN YOU HAVE INHALED MORE THAN THE RECOMMENDED DOSAGE?

If you inhaled more than the recommended dosage, consult a doctor or contact a poison control center right away. Quick medical attention is important if someone has difficulty in breathing.

HOW SHOULD YOU KEEP THIS MEDICINE?

Keep out of reach of children. Keep the medicine in a dry, well-ventilated area at temperatures not exceeding 30°C.

WHEN SHOULD YOU CONSULT YOUR DOCTOR?

Stop use and ask a doctor if difficulty in breathing or new symptoms occur.

GREENSTONE PHARMACEUTICAL

Anabu Industrial Estate, Anabu Hills 1-C, Imus, Cavite

For suspected adverse drug reaction, report to the FDA: www.fda.gov.ph. Seek medical attention immediately at the first sign of any adverse drug reaction.

 

DRHR-1955

Date of First Authorization: 18 Oct 2019

Renewal of the Authorization: 18 Oct 2024
Date of Revision: 23 Jun 2021